William Pao

66.6k total citations · 20 hit papers
230 papers, 35.5k citations indexed

About

William Pao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, William Pao has authored 230 papers receiving a total of 35.5k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Pulmonary and Respiratory Medicine, 121 papers in Oncology and 80 papers in Molecular Biology. Recurrent topics in William Pao's work include Lung Cancer Treatments and Mutations (165 papers), Cancer Genomics and Diagnostics (62 papers) and Colorectal Cancer Treatments and Studies (42 papers). William Pao is often cited by papers focused on Lung Cancer Treatments and Mutations (165 papers), Cancer Genomics and Diagnostics (62 papers) and Colorectal Cancer Treatments and Studies (42 papers). William Pao collaborates with scholars based in United States, China and Germany. William Pao's co-authors include Vincent A. Miller, Mark G. Kris, Gregory J. Riely, Maureen F. Zakowski, Marc Ladanyi, Katerina Politi, Harold Varmus, Juliann Chmielecki, Nicolas Girard and Robert T. Heelan and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

William Pao

227 papers receiving 34.7k citations

Hit Papers

EGF receptor gene mutations are common in lung cancers fr... 1995 2026 2005 2015 2004 2005 2013 2005 2011 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
    2004 3.5k citations William Pao, Vincent A. Miller et al. Proceedings of the National Academy of Sciences profile →
  2. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
    2005 2.8k citations William Pao, Vincent A. Miller et al. profile →
  3. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
    2013 1.9k citations Maria E. Arcila, Camelia S. Sima et al. Clinical Cancer Research profile →
  4. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
    2005 1.2k citations William Pao, Gregory J. Riely et al. profile →
  5. New driver mutations in non-small-cell lung cancer
    2011 875 citations William Pao, Nicolas Girard profile →
  6. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
    2010 857 citations William Pao, Juliann Chmielecki profile →
  7. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
    2009 752 citations Christopher G. Azzoli, Sherman Baker et al. Journal of Clinical Oncology profile →
  8. Acquired resistance to TKIs in solid tumours: learning from lung cancer
    2014 677 citations William Pao et al. profile →
  9. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
    2006 664 citations Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research profile →
  10. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
    2009 644 citations William Pao, Gregory J. Riely et al. Journal of Clinical Oncology profile →
  11. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
    2004 628 citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
  12. Anchored multiplex PCR for targeted next-generation sequencing
    2014 624 citations Juliann Chmielecki, William Pao et al. profile →
  13. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
    2006 623 citations Gregory J. Riely, William Pao et al. Clinical Cancer Research profile →
  14. HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
    2012 555 citations Valentina Pirazzoli, Maria E. Arcila et al. profile →
  15. Syk tyrosine kinase required for mouse viability and B-cell development
    1995 535 citations William Pao et al. profile →
  16. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
    2007 535 citations William Pao, William D. Travis et al. profile →
  17. Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions
    2005 514 citations William Pao, Vincent A. Miller Journal of Clinical Oncology profile →
  18. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
    2010 485 citations Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research profile →
  19. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
    2011 476 citations Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research profile →
  20. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
    2013 366 citations William Pao et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Pao United States 86 24.1k 21.0k 14.2k 8.0k 2.5k 230 35.5k
Gregory J. Riely United States 83 23.7k 1.0× 19.5k 0.9× 11.0k 0.8× 6.7k 0.8× 2.2k 0.9× 363 31.4k
Tetsuya Mitsudomi Japan 92 22.7k 0.9× 18.1k 0.9× 14.6k 1.0× 8.5k 1.1× 2.5k 1.0× 529 36.6k
Lecia V. Sequist United States 73 18.3k 0.8× 19.5k 0.9× 10.3k 0.7× 7.6k 0.9× 1.6k 0.6× 368 30.9k
Vincent A. Miller United States 92 30.6k 1.3× 29.8k 1.4× 16.1k 1.1× 10.5k 1.3× 4.3k 1.7× 478 45.7k
Kazuhiko Nakagawa Japan 80 20.8k 0.9× 22.1k 1.1× 9.9k 0.7× 4.4k 0.6× 2.0k 0.8× 815 32.3k
Enriqueta Felip Spain 75 22.9k 0.9× 23.6k 1.1× 9.0k 0.6× 5.7k 0.7× 2.0k 0.8× 796 33.7k
Rafael Rosell Spain 72 16.6k 0.7× 15.2k 0.7× 10.0k 0.7× 6.0k 0.7× 1.9k 0.8× 546 26.8k
Myung‐Ju Ahn South Korea 81 22.6k 0.9× 22.3k 1.1× 7.5k 0.5× 5.1k 0.6× 1.7k 0.7× 717 32.1k
Fortunato Ciardiello Italy 86 11.8k 0.5× 21.9k 1.0× 13.3k 0.9× 5.5k 0.7× 4.6k 1.8× 643 34.3k
Yasushi Yatabe Japan 84 15.3k 0.6× 14.7k 0.7× 12.1k 0.9× 8.7k 1.1× 4.0k 1.6× 642 31.8k

Countries citing papers authored by William Pao

Since Specialization
Citations

This map shows the geographic impact of William Pao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Pao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Pao more than expected).

Fields of papers citing papers by William Pao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Pao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Pao. The network helps show where William Pao may publish in the future.

Co-authorship network of co-authors of William Pao

This figure shows the co-authorship network connecting the top 25 collaborators of William Pao. A scholar is included among the top collaborators of William Pao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Pao. William Pao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ichihara, Eiki, David Westover, Catherine B. Meador, et al.. (2017). SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research. 77(11). 2990–3000. 104 indexed citations
2.
Amato, Katherine, Shan Wang, Li Tan, et al.. (2016). EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research. 76(2). 305–318. 84 indexed citations
3.
Pirazzoli, Valentina, Deborah Ayeni, Catherine B. Meador, et al.. (2015). Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. Clinical Cancer Research. 22(2). 426–435. 32 indexed citations
4.
Meador, Catherine B., Hailing Jin, Elisa de Stanchina, et al.. (2014). Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics. 14(2). 542–552. 22 indexed citations
5.
Xia, Junfeng, Peilin Jia, Katherine E. Hutchinson, et al.. (2014). A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance. Molecular Cancer Therapeutics. 13(7). 1918–1928. 65 indexed citations
6.
Hutchinson, Katherine E., Doron Lipson, Philip J. Stephens, et al.. (2013). BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition. Clinical Cancer Research. 19(24). 6696–6702. 124 indexed citations
7.
8.
Heuckmann, Johannes M., Hyatt Balke‐Want, Florian Malchers, et al.. (2012). Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants. Clinical Cancer Research. 18(17). 4682–4690. 201 indexed citations
9.
Lovly, Christine M., Johannes M. Heuckmann, Elisa de Stanchina, et al.. (2011). Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors. Cancer Research. 71(14). 4920–4931. 177 indexed citations
10.
Garrett, Joan T., Maria G. Olivares, Cammie Rinehart, et al.. (2011). Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences. 108(12). 5021–5026. 359 indexed citations
11.
Heuckmann, Johannes M., Michael Hölzel, Martin L. Sos, et al.. (2011). ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors. Clinical Cancer Research. 17(23). 7394–7401. 147 indexed citations
12.
Girard, Nicolas, Emil Lou, Christopher G. Azzoli, et al.. (2010). Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report. Clinical Cancer Research. 16(2). 755–763. 70 indexed citations
13.
Oxnard, Geoffrey R., Maria E. Arcila, Camelia S. Sima, et al.. (2010). Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation. Clinical Cancer Research. 17(6). 1616–1622. 485 indexed citations breakdown →
14.
Zhao, Binsheng, Geoffrey R. Oxnard, Chaya S. Moskowitz, et al.. (2010). A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development. Clinical Cancer Research. 16(18). 4647–4653. 82 indexed citations
15.
Girard, Nicolas, Irina Ostrovnaya, Christopher Lau, et al.. (2009). Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers. Clinical Cancer Research. 15(16). 5184–5190. 112 indexed citations
16.
Azzoli, Christopher G., Sherman Baker, Sarah Temin, et al.. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(36). 6251–6266. 752 indexed citations breakdown →
17.
Rudin, Charles M., Érika Ávila-Tang, Curtis C. Harris, et al.. (2009). Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clinical Cancer Research. 15(18). 5646–5661. 123 indexed citations
18.
Pratilas, Christine A., Aphrothiti J. Hanrahan, Ensar Halilovic, et al.. (2008). Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer. Cancer Research. 68(22). 9375–9383. 195 indexed citations
19.
Balak, Marissa N., Yixuan Gong, Gregory J. Riely, et al.. (2006). Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research. 12(21). 6494–6501. 664 indexed citations breakdown →
20.
Lassman, Andrew B., Michael R. Rossi, Lauren E. Abrey, et al.. (2005). Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical Cancer Research. 11(21). 7841–7850. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregory J. Riely Breakdown of academic impact, for papers by Tetsuya Mitsudomi Breakdown of academic impact, for papers by Lecia V. Sequist Breakdown of academic impact, for papers by Vincent A. Miller Breakdown of academic impact, for papers by Kazuhiko Nakagawa Breakdown of academic impact, for papers by Enriqueta Felip Breakdown of academic impact, for papers by Rafael Rosell Breakdown of academic impact, for papers by Myung‐Ju Ahn Breakdown of academic impact, for papers by Fortunato Ciardiello Breakdown of academic impact, for papers by Yasushi Yatabe
Rankless by CCL
2026